Feature | Women's Health | July 03, 2019 | By Samir Parikh

Artificial Intelligence: The Key to Personalized Care

Countless possibilities can impact the future of global healthcare and AI is the first step toward breakthrough that will change the landscape of personalized medicine

Countless possibilities can impact the future of global healthcare and AI is the first step toward breakthrough that will change the landscape of personalized medicine
Samir Parikh

Samir Parikh

Contrary to what many people believe, artificial intelligence (AI) has played a role in breast screening technology for a number of years. Hologic, for example, has been leveraging AI in device development as early as 2006, when it trained its first piece of technology to classify a patient’s breast density through breast tissue pattern and texture analysis. More than a decade later, AI has continued to progress. The benefit of time has not only allowed R&D professionals to learn more about the technology, but has also allowed the AI technology to become more precise thanks to the growing body of images in the database. The industry has carefully watched AI’s technological evolution, slowly showing its support as more benefits are realized, and today we’re seeing many radiologists lean in and embrace AI with open arms.

 

AI’s Impact on Breast Cancer Screening

During the 2018 Radiological Society of North America (RSNA) annual meeting, Hologic polled more than 300 attendees, including radiologists and radiology administrative professionals, and found that all participants agreed that there is an application for AI in breast cancer screening. Additionally, respondents indicated that AI will have the greatest impact in the future on personalized screening pathways through the creation of new risk models. While AI very much has a present-day application, it’s clear that its greatest impact is still yet to come as we strive to deliver more personalized care.

Currently, as we all know, there are standard breast screening guidelines for the “average risk” patient without any known risk factors like a family history of breast cancer and increasing patient age. These are two of the biggest risk factors among building a unique profile indicating how “at-risk” a patient really is, and all factors combined can subsequently influence an individual’s screening protocol — including the age she starts, frequency and even the imaging modality for screening.

Breast density is a specific example of a risk factor where AI is particularly useful for determining a patient’s screening pathway. Women with very dense breasts are four to five times more likely to develop breast cancer than women with less dense breasts, making it important to be able to classify each patient’s density.1,2 Doing so requires the patient to get a mammogram, though. Without AI, radiologists must visually assess the images from the exam to determine a woman’s breast density using the Breast Imaging Reporting and Data System (BI-RADS) founded by the American College of Radiology (ACR) in 1993. Utilizing AI technology, however, removes any subjectivity associated with this manual process by automatically categorizing each patient’s density based on the thousands of breast images that it is trained by radiologists to know. As a result, radiologists can more confidently provide the most appropriate screening plan for each individual moving forward.

Aside from breast density, it has also been suggested in more recent studies that parenchymal texture features, which are measures of the local distribution of the parenchymal tissue, may also provide complementary information regarding an individual woman’s risk for breast cancer.3,4 This is yet another example of how risk stratification is being used, for which AI can offer assistance.

 

AI and Risk Assessment

AI will continue to play a significant role in risk stratification and risk assessment to drive more personalized patient care and outcomes. Patient history, family history, evidence-based clinical conditions, image-based phenotypes (e.g. texture/pattern/AI based features) and many more such attributes and innovations will further augment and strengthen the personalized health profile assessment along with risk models. There are countless possibilities to impact the future of global healthcare and our journey in AI is the first big step toward breakthrough that will change the landscape of personalized medicine. It’s not a matter of “if,” it’s a matter of when.

 

Samir Parikh is the global vice president of research and development for Hologic. In this role, he is responsible for leading and driving innovative advanced solutions across the continuum of care to drive sustainable growth of the Breast and Skeletal Health Division.

 

References:

1. Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 356(3):227-36, 2007.

2. Yaghjyan L, Colditz GA, Collins LC, et al. Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics. J Natl Cancer Inst. 103(15):1179-89, 2011.

3. H. Li et al., “Computerized texture analysis of mammographic parenchymal patterns of digitized mammograms,” Acad. Radiol. 12(7), 863–873 (2005).

4. Manduca et al., “Texture features from mammographic images and risk of breast cancer,” Cancer Epidemiol. Biomarkers Prev. 18(3), 837–845 (2009).

Related Content

Lunit Receives Korea MFDS Approval for Lunit Insight MMG
News | Artificial Intelligence | August 19, 2019
Lunit has announced Korea Ministry of Food and Drug Safety (MFDS) approval of its artificial intelligence (AI) solution...
Imago Systems Announces Collaboration With Mayo Clinic for Breast Imaging

Image courtesy of Imago Systems

News | Mammography | August 14, 2019
Image visualization company Imago Systems announced it has signed a know-how license with Mayo Clinic. The multi-year...
Artificial Intelligence Could Yield More Accurate Breast Cancer Diagnoses
News | Artificial Intelligence | August 13, 2019
University of California Los Angeles (UCLA) researchers have developed an artificial intelligence (AI) system that...
Lake Medical Imaging Selects Infinitt for Multi-site RIS/PACS
News | PACS | August 09, 2019
Infinitt North America will be implementing Infinitt RIS (radiology information system)/PACS (picture archiving and...
Volpara to Distribute Screenpoint Medical's Transpara AI Solution
News | Breast Imaging | August 02, 2019
Volpara Solutions and ScreenPoint Medical BV signed an agreement under which Volpara will sell ScreenPoint's Transpara...
Ikonopedia Releases Automated Combined Reporting Package at AHRA
News | Mammography Reporting Software | July 26, 2019
Ikonopedia showcased its recently released Automated Combined Reporting package and its entire suite of structured...
Hologic Partners With MagView to Develop Unifi EQUIP Solution
Technology | Mammography Reporting Software | July 25, 2019
Hologic announced a partnership with mammography information solutions provider MagView to develop Unifi EQUIP, an...
Fujifilm Releases Tomosynthesis Biopsy Option for Aspire Cristalle Mammography System
Technology | Breast Biopsy Systems | July 24, 2019
Fujifilm Medical Systems U.S.A. Inc. recently expanded its breast imaging solutions with the launch of its...
IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017.

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017, and who had health records for at least one year prior to the mammogram. The algorithm was trained on 9,611 mammograms. Image courtesy of Radiology.

Feature | Artificial Intelligence | July 19, 2019 | Michal Chorev
Breast cancer is the global leading cause of cancer-related deaths in women, and the most commonly diagnosed cancer...
Paragon Biosciences Launches Qlarity Imaging to Advance FDA-cleared AI Breast Cancer Diagnosis System

Qlarity Imaging’s software is used to assist radiologists in the assessment and characterization of breast lesions. Imaging features are synthesized by an artificial intelligence algorithm into a single value, the QI score, which is analyzed relative to a database of reference abnormalities with known ground truth. Image courtesy of Business Wire.

Technology | Artificial Intelligence | July 18, 2019
Paragon Biosciences LLC announced the launch of its seventh portfolio company, Qlarity Imaging LLC, which was founded...